A. Morganti

3.5k total citations · 1 hit paper
26 papers, 2.5k citations indexed

About

A. Morganti is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, A. Morganti has authored 26 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 6 papers in Pathology and Forensic Medicine and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in A. Morganti's work include Pulmonary Hypertension Research and Treatments (12 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Systemic Sclerosis and Related Diseases (5 papers). A. Morganti is often cited by papers focused on Pulmonary Hypertension Research and Treatments (12 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Systemic Sclerosis and Related Diseases (5 papers). A. Morganti collaborates with scholars based in United States, Switzerland and Italy. A. Morganti's co-authors include Ganesh Raghu, Jürgen Behr, Loı̈c Perchenet, Isabelle Leconte, Sébastiên Roux, Laura A. Cisar, Caio M. Rocha Lima, Wilson H. Miller, Mark R. Green and G. Gruia and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

A. Morganti

26 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis

2011 440 citations Talmadge E. King, Kevin M. Brown et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Morganti United States	13	1.7k	622	507	406	321	26	2.5k
Leopold Balleisen Germany	18	742 0.4×	310 0.5×	164 0.3×	287 0.7×	69 0.2×	41	2.1k
Micki Klearman United States	17	1.1k 0.6×	140 0.2×	265 0.5×	200 0.5×	118 0.4×	31	2.7k
Jiuliang Zhao China	24	751 0.5×	199 0.3×	113 0.2×	465 1.1×	154 0.5×	231	2.3k
Marco Gambarotti Italy	28	1.6k 0.9×	306 0.5×	677 1.3×	280 0.7×	70 0.2×	150	2.7k
Patrizia Noris Italy	36	560 0.3×	306 0.5×	181 0.4×	123 0.3×	93 0.3×	91	2.9k
Jean Elwing United States	12	795 0.5×	311 0.5×	295 0.6×	75 0.2×	766 2.4×	60	1.5k
Lisa Wheeler United States	22	2.1k 1.2×	776 1.2×	164 0.3×	53 0.1×	94 0.3×	31	2.4k
Riruke Maruyama Japan	24	471 0.3×	106 0.2×	422 0.8×	159 0.4×	186 0.6×	123	2.1k
Frank Willeke Germany	32	1.1k 0.7×	386 0.6×	1.4k 2.8×	269 0.7×	104 0.3×	102	3.0k
Nisha Nanda United States	14	561 0.3×	164 0.3×	235 0.5×	102 0.3×	94 0.3×	33	1.4k

Countries citing papers authored by A. Morganti

Since Specialization

Citations

This map shows the geographic impact of A. Morganti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Morganti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Morganti more than expected).

Fields of papers citing papers by A. Morganti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Morganti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Morganti. The network helps show where A. Morganti may publish in the future.

Co-authorship network of co-authors of A. Morganti

This figure shows the co-authorship network connecting the top 25 collaborators of A. Morganti. A scholar is included among the top collaborators of A. Morganti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Morganti. A. Morganti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grünig, Ekkehard, Pavel Jansa, Fenling Fan, et al.. (2024). Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 83(4). 473–484. 26 indexed citations

Channick, Richard N., Vallerie V. McLaughlin, Kelly Chin, et al.. (2019). Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Real-World Experience with Macitentan. The Journal of Heart and Lung Transplantation. 38(4). S483–S483. 1 indexed citations

Bauer, Yasmina, Eric S. White, Simon Bernard, et al.. (2017). MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Research. 3(1). 74–2016. 91 indexed citations

Lonati, Chiara, et al.. (2016). [OP.1A.03] CORRELATIONS BETWEEN WHITE-COAT EFFECT AND MORNING BLOOD PRESSURE SURGE ON AMBULATORY BLOOD PRESSURE MONITORING. Journal of Hypertension. 34(Supplement 2). e1–e2. 1 indexed citations

Raghu, Ganesh, et al.. (2013). Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. European Respiratory Journal. 42(6). 1622–1632. 199 indexed citations

King, Talmadge E., Kevin M. Brown, Ganesh Raghu, et al.. (2011). BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 184(1). 92–99. 440 indexed citations breakdown →

Simonneau, Gérald, Nazzareno Galiè, Marius M. Hoeper, et al.. (2011). An Interim Analysis Of Long-Term Outcomes In Patients Treated With Bosentan In The Double-Blind Or Open-Label Extension To The Early Trial. A5886–A5886. 1 indexed citations

Kefford, Richard, et al.. (2010). A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Molecular Cancer. 9(1). 69–69. 38 indexed citations

Matucci‐Cerinic, Marco, CP Denton, D.E. Furst, et al.. (2010). Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 70(1). 32–38. 322 indexed citations

10.

King, Talmadge E., Kevin M. Brown, Ganesh Raghu, et al.. (2010). The BUILD-3 Trial: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Of Bosentan In Idiopathic Pulmonary Fibrosis. A6838–A6838. 3 indexed citations

11.

Beghetti, Maurice, Sheila G. Haworth, Damien Bonnet, et al.. (2009). Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE‐1 study. British Journal of Clinical Pharmacology. 68(6). 948–955. 79 indexed citations

12.

Jaïs, Xavier, Andrea Maria D’Armini, Pavel Jansa, et al.. (2008). Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology. 52(25). 2127–2134. 384 indexed citations

13.

Denton, Christopher P., Janet Pope, HH Peter, et al.. (2007). Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Annals of the Rheumatic Diseases. 67(9). 1222–1228. 108 indexed citations

14.

Kefford, Richard, Jane Beith, Guy A. Van Hazel, et al.. (2006). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs. 25(3). 247–252. 52 indexed citations

15.

Rosenzweig, Erika B., D. Dunbar Ivy, Allison Widlitz, et al.. (2005). Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 46(4). 697–704. 191 indexed citations

16.

Achilli, Felice, et al.. (2004). Arterial stiffness in heart failure patients: dependance on diastolic dysfunction and plasma aldosterone levels. European Heart Journal Supplements. 6. F30–F34. 9 indexed citations

17.

Volpe, Massimo, Giuseppe Lembo, A. Morganti, M Condorelli, & Bruno Trimarco. (1988). Contribution of the Renin-Angiotensin System and of the Sympathetic Nervous System to Blood Pressure Homeostasis During Chronic Restriction of Sodium Intake. American Journal of Hypertension. 1(4 Pt 1). 353–358. 13 indexed citations

18.

Glorioso, Nicola, Paolo Dessı̀-Fulgheri, Paolo Madeddu, et al.. (1986). A reevaluation of methodological aspects of a commercial RIA kit for plasma renin activity.. PubMed. 29(3). 235–9. 2 indexed citations

19.

Tg, Pickering, et al.. (1979). Immediate and delayed hypotensive effects of propranolol at rest and during exercise.. PubMed. 92. 277–85. 2 indexed citations

20.

Leonetti, Gastone, Gert Mayer, A. Morganti, et al.. (1974). Blood Pressure Decrease and Responsiveness to Renin-Releasing Stimuli under Increasing Doses of Propranolol in Patients with Essential Hypertension. Clinical Science. 48(s2). 77s–79s. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact